Narrative review / 2023
Semaglutide reduced body weight by nearly 12% over 68 weeks in clinical trials, but discontinuation led to regaining most of the lost weight.
This review examines semaglutide, approved for type 2 diabetes and obesity management. Manufacturer-sponsored randomized controlled trials showed a loss of almost 12% of body weight over 68 weeks, though individuals regain most of their pretreatment weight once medication is stopped. Gastrointestinal adverse events occur commonly, and pancreatitis, diabetic retinopathy, and severe allergic reactions have also been reported.
- Study type
- Narrative review
- Who was studied
- Individuals who are obese or overweight with at least one weight-related comorbidity
- What was measured
- Body weight loss, weight regain, adverse events
THE PAPER
Semaglutide: a new drug for the treatment of obesity.
Lexchin J, Mintzes B. Drug Ther Bull, 2023.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.